Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Silvia Martina Ferrari, Ugo Politti, Roberto Spisni, Gabriele Materazzi, Enke Baldini, Salvatore Ulisse, Paolo Miccoli, Alessandro Antonelli & Poupak Fallahi. (2015) Sorafenib in the treatment of thyroid cancer. Expert Review of Anticancer Therapy 15:8, pages 863-874.
Read now
Read now
Jeeyeon Kim, Junha Hwang, Hyeseon Jeong, Hee-Jung Song, Jieun Shin, Gangmin Hur, Young Woo Park, Suk Hoon Lee & Jei Kim. (2012) Promoter methylation status of VEGF receptor genes: A possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells. Epigenetics 7:2, pages 191-200.
Read now
Read now
Joel A Lefferts & Gregory J Tsongalis. (2010) Molecular diagnostics: parallels between infectious disease and emerging oncology testing. Expert Opinion on Medical Diagnostics 4:3, pages 185-188.
Read now
Read now
Joanna Wood, Edwina Scott & Anne L Thomas. (2009) Novel VEGF signalling inhibitors: how helpful are biomarkers in their early development?. Expert Opinion on Investigational Drugs 18:11, pages 1701-1714.
Read now
Read now
David A Price, Julian Blagg, Lyn Jones, Nigel Greene & Travis Wager. (2009) Physicochemical drug properties associated with in vivo toxicological outcomes: a review. Expert Opinion on Drug Metabolism & Toxicology 5:8, pages 921-931.
Read now
Read now
Abdul M Oseini & Lewis R Roberts. (2009) PDGFRα: a new therapeutic target in the treatment of hepatocellular carcinoma?. Expert Opinion on Therapeutic Targets 13:4, pages 443-454.
Read now
Read now
Alexandros Lekas, Thomas G Papathomas, Athanasios G Papatsoris, Charalambos Deliveliotis & Andreas C Lazaris. (2008) Novel therapeutics in metastatic bladder cancer. Expert Opinion on Investigational Drugs 17:12, pages 1889-1899.
Read now
Read now
Articles from other publishers (38)
Joseph P. Eder & Navid Hafez. 2017. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine
1
13
.
Yueshan Zhao, Yue Wang, Da Yang, Kangho Suh & Min Zhang. (2022) A Computational Framework to Characterize the Cancer Drug Induced Effect on Aging Using Transcriptomic Data. Frontiers in Pharmacology 13.
Crossref
Crossref
William N. Hait & Joseph P. Eder. 2016. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine
1
15
.
Silvia Martina Ferrari, Marco Centanni, Camilla Virili, Mario Miccoli, Paola Ferrari, Ilaria Ruffilli, Francesca Ragusa, Alessandro Antonelli & Poupak Fallahi. (2019) Sunitinib in the Treatment of Thyroid Cancer. Current Medicinal Chemistry 26:6, pages 963-972.
Crossref
Crossref
C. Requejo, J. A. Ruiz-Ortega, H. Bengoetxea, S. Bulnes, L. Ugedo & J. V. Lafuente. (2017) Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson’s Disease. Molecular Neurobiology 55:1, pages 201-212.
Crossref
Crossref
William N. Hait & Joseph P. Eder. 2016. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine
1
14
.
Giorgio Cozza. (2017) The Development of CK2 Inhibitors: From Traditional Pharmacology to in Silico Rational Drug Design. Pharmaceuticals 10:4, pages 26.
Crossref
Crossref
Luca Carlino & Giulio Rastelli. (2016) Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective. Journal of Medicinal Chemistry 59:20, pages 9305-9320.
Crossref
Crossref
Stuart T. Onions, Kazuhiro Ito, Catherine E. Charron, Richard J. Brown, Marie Colucci, Fritz Frickel, George Hardy, Kevin Joly, John King-Underwood, Yasuo Kizawa, Ian Knowles, P. John Murray, Andrew Novak, Anjna Rani, Garth Rapeport, Alun Smith, Peter Strong, David M. Taddei & Jonathan G. Williams. (2016) Discovery of Narrow Spectrum Kinase Inhibitors: New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma. Journal of Medicinal Chemistry 59:5, pages 1727-1746.
Crossref
Crossref
Andrea Volkamer, Sameh Eid, Samo Turk, Friedrich Rippmann & Simone Fulle. (2016) Identification and Visualization of Kinase-Specific Subpockets. Journal of Chemical Information and Modeling 56:2, pages 335-346.
Crossref
Crossref
E. V. Koroleva, Zh. I. Ignatovich, Yu. V. Sinyutich & K. N. Gusak. (2016) Aminopyrimidine derivatives as protein kinases inhibitors. Molecular design, synthesis, and biologic activity. Russian Journal of Organic Chemistry 52:2, pages 139-177.
Crossref
Crossref
Alexander Kikuchi & Satdarshan Pal Monga. (2015) PDGFRα in Liver Pathophysiology: Emerging Roles in Development, Regeneration, Fibrosis, and Cancer. Gene Expression 16:3, pages 109-127.
Crossref
Crossref
Christopher Merritt, Lisseth E. Silva, Angela L. Tanner, Kenneth Stuart & Michael P. Pollastri. (2014) Kinases as Druggable Targets in Trypanosomatid Protozoan Parasites. Chemical Reviews 114:22, pages 11280-11304.
Crossref
Crossref
Channing J. Paller, Penelope A. Bradbury, S. Percy Ivy, Lesley Seymour, Patricia M. LoRusso, Laurence Baker, Larry Rubinstein, Erich Huang, Deborah Collyar, Susan Groshen, Steven Reeves, Lee M. Ellis, Daniel J. Sargent, Gary L. Rosner, Michael L. LeBlanc & Mark J. Ratain. (2014) Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clinical Cancer Research 20:16, pages 4210-4217.
Crossref
Crossref
Poupak Fallahi, Silvia Martina Ferrari, Francesca Santini, Alda Corrado, Gabriele Materazzi, Salvatore Ulisse, Paolo Miccoli & Alessandro Antonelli. (2013) Sorafenib and Thyroid Cancer. BioDrugs 27:6, pages 615-628.
Crossref
Crossref
Anna Burford, Suzanne E. Little, Alexa Jury, Sergey Popov, Ross Laxton, Lawrence Doey, Safa Al-Sarraj, Juliane M. Jürgensmeier & Chris Jones. (2013) Distinct Phenotypic Differences Associated with Differential Amplification of Receptor Tyrosine Kinase Genes at 4q12 in Glioblastoma. PLoS ONE 8:8, pages e71777.
Crossref
Crossref
Serena Giunti, Alessandro Antonelli, Andrea Amorosi & Libero Santarpia. (2013) Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma. International Journal of Endocrinology 2013, pages 1-16.
Crossref
Crossref
Radoslav Savić & Edward H. Schuchman. 2013. The Role of Sphingolipids in Cancer Development and Therapy. The Role of Sphingolipids in Cancer Development and Therapy
91
115
.
Patricia M. LoRusso, Renzo Canetta, John A. Wagner, Erin P. Balogh, Sharyl J. Nass, Scott A. Boerner & John Hohneker. (2012) Accelerating Cancer Therapy Development: The Importance of Combination Strategies and Collaboration. Summary of an Institute of Medicine Workshop. Clinical Cancer Research 18:22, pages 6101-6109.
Crossref
Crossref
Michael C. Heinrich, Diana Griffith, Arin McKinley, Janice Patterson, Ajia Presnell, Abhijit Ramachandran & Maria Debiec-Rychter. (2012) Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors. Clinical Cancer Research 18:16, pages 4375-4384.
Crossref
Crossref
Priam Villalonga, Silvia Fernández de Mattos, Guillem Ramis, Antònia Obrador-Hevia, Angel Sampedro, Carmen Rotger & Antoni Costa. (2012) Cyclosquaramides as Kinase Inhibitors with Anticancer Activity. ChemMedChem 7:8, pages 1472-1480.
Crossref
Crossref
Jing Huang, Wenze Zhang, Debra Bowen, Joemy Tam, Hsiaohui Wu & Man Fung. (2012) Emerging Trends in US Oncological Approvals: A 13-Year Review (1999–2011). Drug Information Journal 46:3, pages 344-357.
Crossref
Crossref
Alessandro Antonelli, Poupak Fallahi, Silvia Martina Ferrari, Caterina Mancusi, Michele Colaci, Libero Santarpia & Clodoveo Ferri. (2012) RET TKI: Potential Role in Thyroid Cancers. Current Oncology Reports 14:2, pages 97-104.
Crossref
Crossref
Ming-Qiang Zhang. 2012. Chemical Proteomics. Chemical Proteomics
297
307
.
Klaudia Jomova & Marian Valko. 2011. Oxidative Stress in Vertebrates and Invertebrates. Oxidative Stress in Vertebrates and Invertebrates
17
32
.
Carmela Napolitano, Alessandro Natoni, Corrado Santocanale, Lasse Evensen, James B. Lorens & Paul V. Murphy. (2011) Isosteric replacement of the Z-enone with haloethyl ketone and E-enone in a resorcylic acid lactone series and biological evaluation. Bioorganic & Medicinal Chemistry Letters 21:4, pages 1167-1170.
Crossref
Crossref
Florence M. Hofman & Thomas C. Chen. 2011. Methods of Cancer Diagnosis, Therapy, and Prognosis. Methods of Cancer Diagnosis, Therapy, and Prognosis
97
108
.
E. Ardini, P. Magnaghi, P. Orsini, A. Galvani & M. Menichincheri. (2010) Anaplastic Lymphoma Kinase: Role in specific tumours, and development of small molecule inhibitors for cancer therapy. Cancer Letters 299:2, pages 81-94.
Crossref
Crossref
Govindan Subramanian & Manish Sud. (2010) Computational Modeling of Kinase Inhibitor Selectivity. ACS Medicinal Chemistry Letters 1:8, pages 395-399.
Crossref
Crossref
Ronan J. Kelly, Colleen Darnell & Olivier Rixe. (2010) Target Inhibition in Antiangiogenic Therapy A Wide Spectrum of Selectivity and Specificity. The Cancer Journal 16:6, pages 635-642.
Crossref
Crossref
Donald J. AbrahamRobert H. Bradbury. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
295
344
.
Donald J. AbrahamRichard Morphy & Zoran Rankovic. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
249
274
.
Joseph Paul Eder, Geoffrey I. Shapiro, Leonard J. Appleman, Andrew X. Zhu, Dale Miles, Harold Keer, Belinda Cancilla, Felix Chu, Suzanne Hitchcock-Bryan, Laurie Sherman, Stewart McCallum, Elisabeth I. Heath, Scott A. Boerner & Patricia M. LoRusso. (2010) A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2. Clinical Cancer Research 16:13, pages 3507-3516.
Crossref
Crossref
Patricia M. LoRusso, Scott A. Boerner & Lesley Seymour. (2010) An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics. Clinical Cancer Research 16:6, pages 1710-1718.
Crossref
Crossref
Richard Morphy. (2009) Selectively Nonselective Kinase Inhibition: Striking the Right Balance. Journal of Medicinal Chemistry 53:4, pages 1413-1437.
Crossref
Crossref
L. Santarpia, L. Ye & R. F. Gagel. (2009) Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma. Journal of Internal Medicine 266:1, pages 99-113.
Crossref
Crossref
Ronan J. Kelly, Bertrand Billemont & Olivier Rixe. (2009) Renal toxicity of targeted therapies. Targeted Oncology 4:2, pages 121-133.
Crossref
Crossref
Jack A. Bikker, Natasja Brooijmans, Allan Wissner & Tarek S. Mansour. (2009) Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies. Journal of Medicinal Chemistry 52:6, pages 1493-1509.
Crossref
Crossref